Mestane

Exemestane, the active ingredient in Mestane, is a aromatase inhibitor presented as an oral tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Mestane as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Exemestane acts on the estrogen‑dependent pathway of hormone‑sensitive breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces risk of disease recurrence after surgery. - Advanced/metastatic breast cancer (postmenopausal): Provides disease control when combined with other hormonal agents. - Adjuvant endocrine therapy: Complements other treatments to improve overall survival.

Exemestane may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Joint and muscle pain: Arthralgia or myalgia. - Fatigue: Persistent tiredness. - Nausea: Mild to moderate upset stomach. - Headache: Tension‑type or migraine‑like. - Dizziness: Light‑headed sensation.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: Blood clots in veins or lungs. - Severe liver injury: Elevated transaminases or hepatitis. - Bone fractures: Increased risk due to lowered estrogen. - Myocardial infarction: Heart attack events. - Severe allergic reactions: Anaphylaxis or angioedema. - Hyperglycemia: Elevated blood sugar levels.

Before initiating Exemestane therapy, several safety considerations are recommended. - Bone health monitoring: Assess bone mineral density periodically. - Liver function assessment: Perform baseline and periodic liver enzyme tests. - Cardiovascular risk evaluation: Review history of thromboembolic events. - Avoid use in premenopausal women: Not indicated for this population. - Review concomitant hormone therapy: Ensure no estrogen supplementation. - Store at below 25°C: Keep in the original pack, protect from moisture.

Exemestane can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Estrogen‑containing products: Counteracts aromatase inhibition. - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase Exemestane exposure. - Strong CYP3A4 inducers (e.g., rifampin): May reduce therapeutic effect. - Tamoxifen: Antagonistic hormonal actions. - Warfarin: Potential alteration of anticoagulant control.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): May affect hormone levels. - Statins (e.g., simvastatin): Possible increased risk of muscle toxicity. - Glucocorticoids: May influence bone health. - Antihypertensives: Monitor blood pressure changes. - Bisphosphonates: Coordinate bone‑protective strategies.